Skip to main content
Clinical Trials/NCT06621030
NCT06621030
Not yet recruiting
Not Applicable

Evaluation of Correlations Between Volatile Organic Compounds (VOCs) Spectra Measured With GC-IMS and MOx-sensors and Venous Blood Glucose in Subjects With Type 2 Diabetes

BOYDSENSE0 sites15 target enrollmentOctober 1, 2024
ConditionsType 2 Diabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
BOYDSENSE
Enrollment
15
Primary Endpoint
VOC spectra
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this study is to evaluate correlations between VOCs in the breath and venous blood glucose values in various glycaemic states in people living with Type 2 Diabetes. VOCs are measured with a gold-standard GC-IMS device and a prototype of a novel breath analyzer. Participants will be exposed to different blood glucose levels at different rates of change by administering glucose solution and insulin and by a meal challenge.

Detailed Description

The research project aims to expand the understanding of correlations between VOCs in the breath and venous blood glucose levels in non-insulin-dependent people with Type 2 Diabetes. To better understand correlations, the subjects are exposed to hyperglycaemic, euglycaemic and hyposglcycaemic states at different rates of change by applying a hand clamp procedure, and the VOCs are compared after a standardized meal and the same excursion by applying a hand clamp procedure. Inter- and intraparticipant variability as well as the timing of changes in the VOC spectra compared to changes in the glucose values are of interest. Secondarily, the feasibility of estimating glycaemic states with a prototype of a novel breath analyzer is being investigated.

Registry
clinicaltrials.gov
Start Date
October 1, 2024
End Date
March 30, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
BOYDSENSE
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Signed written informed consent
  • T2D treated with one or more oral anti-diabetic drugs (incl GLP-1 and/or GIP)
  • 10 years since T2D diagnosis
  • HbA1c ≤8% (HbA1c based on last measurement by treating physician but not older than 120 days)
  • Willingness to undergo study procedures
  • Age 45 -70 years (inclusive)

Exclusion Criteria

  • Pregnancy and/or lactation period
  • Currently on chronic or occasional treatment with pulmonary drugs
  • Insulin dependency
  • Smoking (last cigarette within the last six months)
  • BMI above 30 kg/m²
  • Lp(a) above 125 nmol/l
  • LDL not in the individual target range of an earlier cholesterol goal according ESC guideline 2021 (LDL based on last measurement by treating physician but not older than 30 days)
  • Irregular 12-lead ECG or increased carotid plaque burden based on a three-point sonography. Both examinations are performed and evaluated according to the investigator's judgment.
  • History of, or manifested, cardiovascular diseases
  • Medical history of epilepsy or other neurological disease associated with seizure events

Outcomes

Primary Outcomes

VOC spectra

Time Frame: 6-8 hour study visit

Primary outcome focuses on VOC spectra (measured with the GC-IMS) across varying intravenous blood glucose levels

Secondary Outcomes

  • Inter-Participant VOC Variability(6-8 hour study visit)
  • Intra-Participant VOC Variability(6-8 hour study visit)
  • MIB VOC Spectra Analysis(6-8 hour study visit)
  • VOC Spectra Response Time(6-8 hour study visit)
  • Comparison of meal vs clamp induced VOC changes(6-8 hour study visit)

Similar Trials